Show simple item record

dc.contributor.authorBerasategui, Bárbara
dc.contributor.authorFonollosa Calduch, Alejandro
dc.contributor.authorArtaraz Beobide, Joseba Iñaki
dc.contributor.authorRuiz Arruza, Ioana
dc.contributor.authorRíos, José
dc.contributor.authorMatas, Jessica
dc.contributor.authorLlorenç, Victor
dc.contributor.authorDiaz-Valle, David
dc.contributor.authorSastre-Ibañez, Marina
dc.contributor.authorArriola-Villalobos, Pedro
dc.contributor.authorAdan, Alfredo
dc.date.accessioned2018-11-22T13:42:08Z
dc.date.available2018-11-22T13:42:08Z
dc.date.issued2018-07-20
dc.identifier.citationBMC Ophthalmology 18 : (2018) // Article ID 179es_ES
dc.identifier.issn1471-2415
dc.identifier.urihttp://hdl.handle.net/10810/29749
dc.description.abstractBackground: Hyperreflective foci have been described in OCT imaging of patients with retinal vascular diseases. It has been suggested that they may play a role as a prognostic factor of visual outcomes in these diseases. The purpose of this study is to describe the presence of hyperreflective foci in patients with non-infectious uveitic macular edema and evaluate their behavior after treatment. Methods: We conducted a multicenter, prospective, observational, 12-month follow-up study. Inclusion criteria were age > 18 years and a diagnosis of non-infectious uveitic macular edema, defined as central macular thickness of > 300 mu m as measured by OCT and fluid in the macula. Collected data included best corrected visual acuity, central macular thickness and the presence, number and distribution (inner or outer retinal layers) of hyperreflective foci. Evaluations were performed at baseline, and at 1, 3, 6, and 12 months after starting treatment. Results: We included 24 eyes of 24 patients. The frequency of patients with >= 11 hyperreflective foci was 58.4% at baseline, falling to 20.8% at 12 months. Further, hyperreflective foci were observed in the outer retinal layers in 50% of patients at baseline and just 28.6% at 12 months. Mean LogMAR visual acuity improved from 0.55 (95% CI 0.4-0. 71) at baseline to 0.22 (95% CI 0.08-0.35) at 12 months (p < 0.001). Mean central macular thickness decreased from 453.83 mu m (95% CI 396.6-511) at baseline to 269.32 mu m (95% CI 227.7-310.9) at 12 months (P < 0.001). Central macular thickness was associated with number (p = 0.017) and distribution (p = 0.004) of hyperreflective foci. Conclusions: We have observed hyperreflective foci in most of our patients with non-infectious uveitic macular edema. During follow-up and after treatment, the number of foci diminished and they tended to be located in the inner layers of the retina.es_ES
dc.description.sponsorshipThis work was supported by grants from: Spanish Ministry of Economy, Industry and Competitivity, Carlos III Health Institute: PI 13/02148, cofinanced by the European Regional Development Fund.es_ES
dc.language.isoenges_ES
dc.publisherBiomed Centrales_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/PI 13/02148es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjecthyperreflective focies_ES
dc.subjectintraocular inflammationes_ES
dc.subjectmicrogliaes_ES
dc.subjectoptical coherence tomographyes_ES
dc.subjectuveitic macular edemaes_ES
dc.subjectuveitises_ES
dc.subjectoptical coherence tomographyes_ES
dc.subjectretinal vein occlusiones_ES
dc.subjectvisual outcomeses_ES
dc.subjectdiabetic-retinopathyes_ES
dc.subjectdegenerationes_ES
dc.subjectmicrogliaes_ES
dc.subjectdexamethasonees_ES
dc.subjectspotses_ES
dc.titleBehavior of hyperreflective foci in non- infectious uveitic macular edema, a 12- month follow-up prospective studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-018-0848-5es_ES
dc.identifier.doi10.1186/s12886-018-0848-5
dc.departamentoesDermatología, oftalmología y otorrinolaringologíaes_ES
dc.departamentoeuDermatologia, oftalmologia eta otorrinolaringologiaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Except where otherwise noted, this item's license is described as This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.